TURBT Important Tool

April 20, 2017
by Stephanie Chisolm

URO Today  article notes that the precise and thorough resection (TURBT) of all existing tumors remains a critical factor influencing bladder cancer patient outcomes. It can not only reduce the incidence of under-staging, but also can provide the optimal setting for adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.) Enhanced cystoscopy has a critical role to play in helping urologists in this area, as recommended by the updated AUA/SUO guidelines on NMIBC. Read the article by BCAN Scientific Advisory Board member Ashish Kamat, MD and Kamal Pohar, MD here. Share this page:

Read More...

BCAN Launches My Bladder Cancer Story

February 21, 2017
by Stephanie Chisolm

This year, over 79,000 people will be diagnosed with bladder cancer. BCAN understands that there are real people behind this number. Our ‘My Bladder Cancer Story’ Campaign presents stories to raise awareness and call attention to the lives and daily experiences of bladder cancer patients and families nationwide. Read the stories            Share your Story Share this page:

Read More...

BMS Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

February 3, 2017
by Stephanie Chisolm

BCAN applauds the U.S. Food and Drug Administration (FDA) for approving Opdivo for use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. “Although bladder cancer is the 5th most commonly diagnosed cancer in the United States, it is only recently that we are starting to see new treatments being approved to help patients with this disease,” according to Andrea Maddox-Smith, CEO of BCAN.  “The FDA’s approval of Opdivo offers a much-needed treatment option for the…

Read More...

BCAN Launches Winter Webinar Series!

December 13, 2016
by Stephanie Chisolm

Wondering what to do on chilly winter nights this January and February? Wish you knew more about bladder cancer? Sign up now for our Bladder Cancer 2017 Winter Webinar Series. We bring the experts to you! You don’t even have to shovel the walk or leave your home to join us for these free Patient Insight Webinars. Make some hot chocolate, grab a blanket and your computer. Leading bladder cancer experts will answer your questions about pathology, bladder removal, and sexuality. To see the full details and to register Click here   Share this page:

Read More...

Dr. Neal Shore appointed to BCAN Board of Directors

November 28, 2016
by Stephanie Chisolm

Bladder Cancer Advocacy Network is pleased to announce the appointment of Neal D. Shore, MD, to its Board of Directors. Dr. Shore is an internationally recognized expert and researcher in systemic therapies for advanced urologic cancers. The medical director of the Carolina Urologic Research Center, he practices with Atlantic Urology Clinics in Myrtle Beach, S.C.  Dr. Shore brings extensive experience and expertise to the BCAN Board of Directors. He has conducted more than 250 clinical trials, focusing mainly on genitourinary oncology and has more than 125 peer-reviewed publications and numerous book chapters. He serves on several industry advisory boards; he is the…

Read More...

Scenes from the Summit!

November 9, 2016
by Stephanie Chisolm

The first annual BCAN Leadership Summit took place this October. More than 60 patient advocates from as far away as Washington State traveled to Rockville, Maryland, for the event. The Bladder Cancer Leadership Summit was designed to engage, educate and energize bladder cancer survivors and volunteers. Participants attended BC–A–N How-To Workshops.  Learning how to communicate to raise awareness in a digital world; advocate on behalf of the bladder cancer community; and navigate the current healthcare system to help bladder cancer patients receive the best care. Take a moment to check out the slide presentations (in blue) listed below each presenter:     Mark Story…

Read More...

Press Release: FDA Approves New Bladder Cancer Treatment

May 18, 2016
by Andrea Maddox-Smith

The Bladder Cancer Advocacy Network (BCAN) applauds the U.S. Food and Drug Administration (FDA) approval of an innovative, first-of-its-kind bladder cancer treatment, establishing a brand new class of therapy for the disease. Genentech, a member of the Roche Group, produced this new treatment, TECENTRIQ™ (atezolizumab), which allows the body’s immune system to work more effectively to fight cancer.

Read More...